Status regarding Novo Nordisk's holding of its own shares (30
September 2008)
In continuation of the company's announcement dated 7 August 2008
concerning a planned share repurchase programme, and pursuant to
Section 204.25 of the New York Stock Exchange Listed Company Manual,
this is to report that Novo Nordisk A/S (NYSE: NVO) and its
wholly-owned affiliates on 30 September 2008 owned 22,989,460 of its
own B shares of DKK 1, corresponding to a total nominal value of DKK
22,989,460 or 3.63% of the total share capital.
In the second quarter of 2008 a total of 6,525,300 B shares were
repurchased, and 107,270 B shares were disposed of to employees in
connection with employee incentive programmes.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,550
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
For further information please contact:
Media: Investors:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisik.com
In North America:
Sean Clements
Tel: (+1) 609 514 8316
secl@novonordisk.com
Company Announcement no 63 / 2008